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The eukaryotic translation elongation factor 1A (eEF1A) has two cell-type specific paralogs, 
eEF1A1 and eEF1A2. Both paralogs undertake a canonical function in delivering aminoacyl-tRNA 
to the ribosome for translation, but differences in other functions are emerging. eEF1A1 has been 
reported to be important for the replication of many viruses, but no study has specifically linked the 
eEF1A2 paralog. We have previously demonstrated that eEF1A1 directly interacts with HIV-1 RT 
and supports efficient reverse transcription. Here, we showed that RT interacted more strongly with 
eEF1A1 than with eEF1A2 in immunoprecipitation assay. Biolayer interferometry using eEF1A 
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paralogs showed different association and dissociation rates with RT. Over expressed eEF1A1, but 
not eEF1A2, was able to restore HIV-1 reverse transcription efficiency in HEK293T cells with 
endogenous eEF1A knocked-down and HIV-1 reverse transcription efficiency correlated with the 
level of eEF1A1 mRNA, but not to eEF1A2 mRNA in both HEK293T and primary human skeletal 
muscle cells.  
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The eukaryotic translation elongation factor 1A (eEF1A) is a highly abundant cellular protein 
involved in delivering aminoacyl-tRNAs to ribosomes for polypeptide synthesis. It is encoded by 
two single copy gene paralogs, EEF1A1 and EEF1A2, located on chromosomes 6q13 and 20q13.33 
respectively. EEF1A1 and EEF1A2 are present in all vertebrates. The amino acid sequence of the 
two human eEF1A paralogs, eEF1A1 (A1) and eEF1A2 (A2), have 92% identity and 98% similarity, 
but the paralogs are differentially expressed in certain cell types. A2 is expressed in terminally 
differentiated muscle, heart, neuronal tissue and in some specialized cells of pancreatic islet and gut 
tissues, whereas A1 is expressed in all other cell types (Soares and Abbott, 2013). The differential 
expression of eEF1A paralogs is regulated during embryogenesis where A1 is initially expressed but 
its expression is replaced by A2 in the cell types described above once terminal differentiation is 
achieved. In addition to the canonical role in protein synthesis, eEF1A1 has a growing list of 
additional, but sometimes interlinked functions, including protein degradation (Gonen et al., 1994; 
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Hotokezaka et al., 2002), cellular apoptosis (Chang and Wang, 2007; Ruest et al., 2002), 
nucleocytoplasmic trafficking (Khacho et al., 2008; Kohler and Hurt, 2007; Murthi et al., 2010), heat 
shock responses (Shamovsky et al., 2006), and multiple aspects of cytoskeletal regulation (Kim and 
Coulombe, 2010), highlighting its importance in diverse cellular processes (Mateyak and Kinzy, 
2010). While previous functional studies of eEF1A focused primarily on the A1 paralog, emerging 
data shows that the A2 paralog has distinct functions to A1 (Hotokezaka et al., 2002; Novosylna et 
al., 2017; Soares and Abbott, 2013; Soares et al., 2009). For example, the appearance of A2 in the 
tissue where it is not normally expressed is thought to be related to tumour development (Abbas et 
al., 2015; Hassan et al., 2018). Another example is where A1 but not A2 plays a regulatory role in 
heat shock response (Vera et al., 2014). 
eEF1A is reported to be involved in the replication of several viruses by distinct mechanisms. 
Accumulating reports indicated that eEF1A can interact with HIV-1 Gag, integrase, Nef and RT 
proteins, as well as HIV-1 genomic RNA to perform multiple roles in HIV-1 replication (Abbas et 
al., 2012; Li et al., 2013; Li et al., 2015a). eEF1A was detected in purified HIV particles, but not 
murine leukaemia virus (MLV) particles, suggesting that eEF1A is incorporated specifically into 
HIV particles and this incorporation is dependent on HIV Gag and  RNA (Cimarelli and Luban, 
1999). Recently we showed that eEF1A also binds to HIV-1 genomic RNA and was important for 
reverse transcription (Li et al., 2015a). Since most primary cells and cell lines used for these virus 
infection studies express exclusively or predominately A1, the reported functions of eEF1A in virus 
replication is presumed to be the A1 paralog (Li et al., 2013; Nagy, 2015), even though many 
immortal cell lines also express varying levels of A2. It is unknown if A2, like A1, functions in the 
replication of viruses. It remains an important and interesting question whether the cell type specific 
expression of certain eEF1A paralogs can explain differences in virus cytotropism for different cells 
in the body. Whether A1, A2 or other cellular factors play roles in the cytotropism and productive 
verse non-productive HIV-1 infection is an unanswered question (Bissel and Wiley, 2004). 
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We have demonstrated that eEF1A can interact with HIV-1 reverse transcriptase (RT) and is 
incorporated in reverse transcription complexes (RTCs) in HEK293T and Jurkat CD4
+
 T cells, both 
of which express predominantly eEF1A1 (Warren et al., 2012). We have previously shown that this 
interaction has important roles in HIV-1 reverse transcription and replication (Li et al., 2015b; Rawle 
et al., 2018; Warren et al., 2012). While a role for eEF1A in reverse transcription may be facilitated 
by interactions in virions, proposed and experimentally supported models of uncoating suggest the 
viral core, a capsular structure composed of capsid protein, becomes “leaky” after 30 minutes 
(Francis and Melikyan, 2018; Mamede et al., 2017), which could also enable RTC interaction with 
cytoplasmic pools of eEF1A and completion of reverse transcription. 
The current study compared the interaction of HIV-1 RT with the two eEF1A paralogs and 
investigated effects of their overexpression or knockdown in HIV-1 reverse transcription. The 
eEF1A1 paralog maintained a tighter interaction with HIV-1 RT, and efficiency of reverse 
transcription correlated with the level of A1, but not A2, in both the human HEK293T cell line and 




2.1. HIV-1 RT interacts with eEF1A1 tighter than eEF1A2 in HEK293T cells. Previously we 
reported that HIV-1 RT and endogenous eEF1A can be co-immunoprecipitated (co-IP) by an anti-
eEF1A antibody from cell lysates (Li et al., 2015b). To examine whether A2 is also able to bind to 
RT, a co-IP assay was used. A1 or A2, which were each C-terminally FLAG-tagged, were 
individually co-expressed with V5 epitope tagged HIV-1RT p51 subunit in HEK293T cells. Western 
blot showed that the levels of RT were similar in all cell lysates tested (Figure 1A), and FLAG-
tagged A1 and A2 were expressed similarly (Figure 1B). Cell lysates were prepared for co-IP 
reactions using a rabbit anti-FLAG antibody. The level of RT in the co-IP product was determined 
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by western blot using a mouse anti-V5 antibody. Western blot of these co-IP reactions showed a 
significantly decreased association of RT with A2 compared to A1 (Figure 1D and 1F), even though 
more A2-FLAG was present in the co-IP than A1-FLAG (Figure 1E). The results indicate that, like 
A1, A2 can bind to RT, albeit at a substantially lower level. 
 
2.2. Purified eEF1A1 and eEF1A2 proteins from mouse tissues show distinct profiles of RT 
binding in biolayer interferometry (BLI) assays. The overexpression of A1 and A2 in HEK293T 
cells occurs in a background of endogenous eEF1A protein, predominantly the A1 paralog. To 
overcome eEF1A paralog co-expression that could complicate binding kinetic analysis of eEF1A to 
RT, cellular A1 and A2 proteins were purified from adult mouse liver that only expresses A1, and 
adult mouse skeletal muscle that only expresses A2 (Yaremchuk et al., 2012). Mouse and human 
eEF1A1 and 1A2 are almost identical, however it has a single amino acid difference between species 
for both paralogs. The purified protein underwent SDS-PAGE and was stained with Coomassie 
brilliant blue reagent. A 50 kDa protein corresponding to the molecular mass of eEF1A was detected 
(Figure 2A), and was identified by western blot using a goat anti-eEF1A antibody, which detects 
both paralogs, and an A2 specific anti-eEF1A antibody as shown (Figure 2B).  
Since there is no specific subtype antibody for eEF1A1, we used RT-qPCR to specifically 
measure the level of A1 and A2 mRNA in the tissues as a way to gauge relative expression of each 
paralog. The primers from different regions of A1 and A2 mRNA were compared and one set of 
primers that gave the best sensitivity and specificity of detection for A1 and A2 were selected 
(Supplementary Table 1). Total RNA was extracted from mouse liver and skeletal muscle tissues and 
the level of A1 and A2 mRNA were determined using RT-qPCR. The result showed that A1 mRNA 
(Soares and Abbott, 2013) is dominant in liver tissue and A2 mRNA is dominant in skeletal muscle 
(Figure 2C).  
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The binding kinetics of HIV-1 RT with purified A1 and A2 was determined by biolayer 
interferometry (BLI) assays using the Octet system as described previously (Li et al., 2015b). In this 
assay, the RT heterodimer was biotinylated and bound to a streptavidin-coated biosensor. The 
interaction of RT with cellular A1 or A2 was examined by immersion of the biosensor into solutions 
containing 90 nM, 30 nM and 10 nM of each protein (Figure 2D). The analysis of three independent 
experiments shown in table 1 measured an association rate (ka) of A2 and RT that rapidly reached a 
plateau, and which exceeded the ka of A1 and RT by 3-fold. However the dissociation rate (kd) of A2 
and RT was ~6-fold higher than the kd of A1 and RT. During the dissociation phase, the binding of 
A1 and RT was measurably higher than A2 and RT at every protein concentration tested. Hence 
although the affinity constants are somewhat similar, where both have very strong low nm KD values, 





Table 1. Association and dissociation parameters of eEF1A1 and eEF1A2 with RT in BLI assay 
protein ka (1/MS) 
(1)
 kd (1/second) 
(2)
 KD (nM) 
(3)
 χ2  (4) 
eEF1A1 9.60 ± 3.54×10
4
 1.05 ± 0.11×10
-4
 1.23 ± 0.55 1.29 ± 1.16 
eEF1A2 2.91 ± 0.41×10
5
 6.55 ± 0.33×10
-4
 2.31 ± 0.41 6.09 ± 2.03 
(1) association rate constants (ka): The rate of complex formed per second in a 1 molar solution of each component. 
(2) dissociation rate constant (kd): Stability of the complex, i.e. the fraction of complex decays per second. 
(3) affinity constant (KD): KD= kd/ka. Significant difference between eEF1A1 and eEF1A2 (p<0.05) 
(4) chi-square test: the goodness of curve fit, where below 10 is considered acceptable (Herschhorn et al., 2008) . 
 
2.3. Exogenously overexpressed eEF1A1, but not eEF1A2, restores HIV-1 reverse transcription 
efficiency in cells with endogenous eEF1A1 downregulated. We had previously demonstrated that 
knockdown of endogenous A1 in HEK293T cells by siRNA treatment impaired HIV-1 reverse 
transcription efficiency (Warren et al., 2012). Since the A2 paralog co-immunoprecipitated with RT 
less than the A1 paralog, we performed experiments to examine whether exogenous overexpression 
of A1 and A2 could restore HIV-1 reverse transcription efficiency in cells where levels of 
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endogenous A1 were downregulated in HEK293T cells. The nucleotide sequence of an A1 cDNA 
was mutated to use alternative codons that would make the transcribed mRNA resistant to the A1 
siRNA used in the experiments (ResA1). ResA1 or A2 were C-terminally fused in frame with 
mCherry (mCh) via a T2A ribosomal skipping sequence making mCh-T2A-ResA1 and mCh-T2A-
A2 (Figure 3A). The T2A sequence allows for independent translation of eEF1A and mCherry.  
HEK293T stable cell lines expressing exogenous ResA1 or A2 were obtained by transduction 
with a lentiviral vector and purified by FACS sorting for mCherry expression. Non-transduced 
HEK293T cells and stable cell lines expressing exogenous ResA1 or A2 were treated with a siRNA 
targeting endogenous eEF1A1 (siRNAA1), or with a non-specific control siRNA (siRNAC), and then 
infected using HIV-1pNL4-3.Luc.R-E- pseudotyped with VSV-G. The virus infections were synchronised 
for entry and each infection was continued for 4 h and then cell lysates were made. The level of total 
eEF1A protein in each lysate was measured by western blot (Figure 3B). The levels of β-tubulin in 
each sample indicated that the amount of lysate used were similar (Figure 3B, bottom panel). ImageJ 
software (Schneider et al., 2012) was used to measure the level of eEF1A in each lane relative to the 
cell only sample (Figure 3, lane 1), with each value normalized to levels of -tubulin in that sample. 
The amount of A1 in cell lysate decreased by ~80% in cells treated with siRNAA1 compared to the 
control siRNAC (Figure 3B, lane 1 vs. lane 4). However, the levels of exogenous overexpressed 
ResA1 and A2 were not affected by either siRNA treatment (Figure 3, lanes 2 and 3 vs. 5 and 6), and 
more eEF1A protein was detected in those cell lysates compared to the cell only control (Figure 3B, 
lane 1).  
The levels of HIV-1 reverse transcription products in the cell lysates were measured by qPCR 
including the early DNA (negative strand strong stop DNA) (Figure 3C), and the late DNA (second 
strand transfer DNA) (Figure 3D). All qPCR measurements were normalized to cytochrome c 
oxidase subunit II DNA levels in each sample. The reverse transcription efficiency refers to the ratio 
of late DNA to early DNA (Figure 3D). The knockdown of endogenous A1 in HEK293T cells with 
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siRNAA1 resulted in a modest change in early DNA level in HEK293T cells (Figure 3C), although 
the difference was not statistically significant. The level of late DNA was significantly lower when 
cells were treated with siRNAA1 compared to siRNAc (Figure 3D), as observed previously (Warren et 
al., 2012). Levels of late DNA were restored by overexpression of exogenous Res-A1 (Figure 3D). A 
small increase in late DNA levels was observed when A2 was overexpressed, but this was not 
statistically significant (Figure 3D). Finally, the reverse transcription efficiencies, which is the 
percentage of late DNA copies to early DNA copies, showed a similar pattern to the late DNA levels 
(Figure 3E), where siRNAA1 inhibited reverse transcription efficiency, which was significantly 
increased when Res-A1 was overexpressed, and not significantly increased by eEF1A2 
overexpression. The results suggest that the more stable interaction of the A1 paralog with RT 
improves reverse transcription, as only Res-A1 could restore HIV late DNA synthesis in cells in a 
statistically significant manner when A1 levels were downregulated by siRNAA1. 
Total RNA was extracted from the siRNA treated and HIV infected HEK 293T cells and 
reverse transcribed to cDNA using random primers followed by specific measurement of eEF1A1 
and A2 mRNA using qPCR. The GAPDH mRNA was also measured and used as an internal control. 
The relative level of A1 mRNA was 30 fold higher than A2 in HEK293T cells (Figure 4). A1 siRNA 
treatment reduced A1 mRNA levels by 83%, which was similar to the measured decrease in A1 
protein levels (Figure 3B). The correlation analysis of A1 or A2 mRNA levels with the efficiency of 
HIV-1 reverse transcription showed that the level of A1 is correlated with reverse transcription 
efficiency (r2=0.655, Figure 4A), but A2 is not (r2=0.059, Figure 4B). These results confirmed the 
finding at the mRNA level that A1, not A2 is crucial for efficient HIV reverse transcription. 
 
2.4. Primary human skeletal muscle cells (SKMC) express dominantly A1, not A2 when the 
cells were cultured in the growth medium and differentiated to myotubes. The results from 
HEK293T cells demonstrated that the level of A1, not A2 protein is important for HIV-1 reverse 
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transcription. We planned to test this finding in an A2 paralog dominant cellular environment. Since 
skeletal muscle cells are reported to express only A2, we explored a primary human skeletal muscle 
cell (SKMC) culture system to examine the effect of A2 on HIV-1 reverse transcription. The cells 
were cultured in SKMC growth medium following the product protocol. The cellular RNA was  
extracted when the cell confluence reached 70% at day 4 and 90% at day 5 of culture followed by 
RT-qPCR to determine the level of A1 and A2. Surprisingly, similar to HEK293T cell line, the 
relative level of A1 is substantially higher than A2 in SKMCs (Table 2).   
Table 2.  Relative levels of A1 and A2 in SKMCs and differentiated myotubes 
                      4 days of culture             5 days of culture 
     Growth                   Differentiation 
    medium                   medium 
    Growth                             Differentiation 
    medium                            medium  
     A1/GAPDH
1
 2.1979±0.1155 5.9835±0.1287 2.07±0.1234 5.3172±0.1178 
A2/GAPDH
1
 0.0014±0.0001 0.0259±0.0033 0.0014±0.0001 0.0245±0.0011 
A1/A2
2
 1592.96±69.926 232.9±22.174 1487.15±105.553 216.97±7.41 
 
1. Ratio of A1 or A2 mRNA copy number/GAPDH mRNA copy number. 
2. Ratio of the relative level of A1/A2  
A previous study showed that the mouse and rat derived skeletal myoblast cell lines can differentiate 
into multinucleated myotubes in vitro, which results in increasing level of A2 and decreasing level of 
A1 (Ruest et al., 2002). Therefore we differentiated the primary human SKMCs to myotubes by 
replacing SKMC growth medium when the cells reached 50% confluence with fusion medium 
following the manufacturer instructions. At day 4 and 5 post-differentiation, the multinucleated 
myotubes were formed and the cellular RNA was extracted to examine the relative levels A1 and A2 
mRNA by RT-qPCR. The results showed that relative levels of A2 mRNA (relative to GAPDH 
mRNA) increased around 20 fold (Table 2) at day 4 or day 5 of differentiation. Compared with the 
cells cultured in growth medium, the ratios of A1/A2 mRNA dropped from 1373~1554 to 214~229. 
The experiment revealed that A1 paralog is dominant in SKMCs, even after they differentiate to 




2.5. HIV-1 reverse transcription efficiency is also correlated with the level of A1, not A2 in 
SKMCs.  Even though SKMCs still predominantly expressed the A1 paralog, we determined the 
reverse transcription efficiency and infectivity in these cells to confirm the results in a primary cell 
that has not been previously used to investigate HIV-1 reverse transcription efficiency. To determine 
the HIV-1 reverse transcription efficiency in SKMCs, cells were transduced with the same lentiviral 
vectors as previously described (Figure 3A) to overexpress A1 with the ResA1 gene or A2. The 
transduced cells are referred to as SKMCs-ResA1 and SKMCs-A2, respectively. SKMCs that 
overexpressed mCh only (SKMCs-mCh) were also produced as a control. Fluorescent microscopy 
indicated that mCh was present in all visible SKMCs (supplementary Figure 1).The levels of A1 and 
A2 mRNA from each of the SKMCs were measured using paralog specific primers in RT-qPCR and 
this was normalised to the level of GAPDH mRNA. The level of A1 mRNA was approximately 
1000-fold higher than A2 in primary human SKMCs (supplementary Figure 2), and increased 3-fold 
in SKMC-A1 where A1 gene was transduced, whereas SKMC-A2 cells expressed approximately 
500-fold higher levels of A2 mRNA after transduction. 
The HIV-1 reverse transcription in SKMC was examined as previously described for 
HEK293T cells. In parallel samples, the infections were incubated for 24 h before a cell lysate was 
made for detection of firefly luciferase, which reports on successful infection and gene expression by 
integrated proviral DNA. The qPCR results showed that HIV-1 early DNA was not significantly 
different between each cellular condition (Figure 5A). However late DNA was significantly 
increased in SKMCs-ResA1 cells (Figure 5B) compared to controls. This difference resulted in 
increased reverse transcription efficiency in HIV-1 infected SKMC-ResA1 cells compared to all 
other SKMCs tested (Figure 5C). Although there was 500 fold more A2 mRNA in SKMCs-A2 cells, 
there was no significant change in HIV-1 reverse transcription. This data was mirrored by luciferase 
expression in HIV-1 infected SKMCs, SKMCs-mCh, SKMCs-ResA1 and SKMCs-A2, where 
luciferase levels were highest in SKMCs-ResA1 cells (p<0.05, Figure 5D). Correlation analysis 
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showed that the reverse transcription efficiency is highly correlated with the level of A1 (r2=0.832) , 
but not A2 mRNA (r2=0.024) in this SKMC culture system (Supplementary Figure 2). The results 
confirm the data from HEK293T cells, supporting the conclusion that the A1 paralog has superior 




Evidence that eEF1A plays important roles in the replication of different RNA viruses is growing 
(reviewed in Li et al., 2013). For example, investigators have reported interaction between eEF1A 
and the RNA polymerases of various RNA viruses that facilitates their replication (Li et al., 2013). 
However, most studies have been performed with various transformed cell lines that express A1 and 
often some level of A2 (Acel et al., 1998; Carr et al., 2008; Qanungo et al., 2004), where the relative 
ratio of the two paralogs expressed by different cell lines is not well documented. Our previous 
analysis indicated that HEK293T cells used in this study primarily express A1 as determined by 
siRNA knockdown experiments that specifically targeted A1 (Warren et al., 2012). Our previous 
studies demonstrated that A1 interacts with HIV-1 RT and that siRNA down-regulation of A1 in 
cells subsequently infected with HIV-1 significantly decreased their reverse transcription (Li et al., 
2015b; Warren et al., 2012). We believe the same is true for Jurkat cells, where our mass 
spectrometry analysis identified the A1 paralog, but not the A2 paralog, as being in the Jurkat cell 
lysate fraction that stimulated reverse transcription (Warren et al., 2012). Here we compared 
interaction of A1 and A2 with HIV-1 RT and evaluated their ability to support HIV-1 reverse 
transcription. 
We observed that IP of A1 results in much higher amounts of co-IP RT compared to IP of 
A2. The BLI experiments were performed using highly purified mouse liver or muscle to obtain A1 
or A2, respectively, where RT was immobilized on a biosensor in a low ionic strength buffer. In this 
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case, the KD measured for the RT:A1 and RT:A2 interactions were similar, 1.2 nM and 2.3 nM 
respectively, and close to the KD measured in a previous study that used commercial FLAG-tagged 
A1, 3.75 nM (Li et al., 2015b). However the ka and kd values for A1 and A2 interactions with RT 
were remarkably dissimilar. The kinetic experiments showed rapid association and dissociation of 
A2 to RT compared to A1, where the association rate was 3-fold faster and dissociation rate of the 
eEF1A2:RT complex was 6-fold faster. This kinetic change was reminiscent of the interaction 
between RT and A1 when a single point mutation in RT, E300R, which had poor binding to eEF1A 
by co-IP and had increased dissociation rate with eEF1A in BLI while the association rate was 
unchanged (Rawle et al., 2018). This may suggest that a stable RT:eEF1A1 interaction which 
dissociates slowly is more important than the association. The binding kinetics profiles suggest that 
different mechanisms regulate interaction of the two eEF1A paralogs with RT.  
The RT:eEF1A1 interaction is important for HIV-1 reverse transcription (Li et al., 2015b; 
Warren et al., 2012) as demonstrated in our recent report that the E300R mutation in RT disrupts the 
RT:eEF1A interaction and results in a significant decrease of HIV-1 reverse transcription efficiency 
and defective replication (Rawle et al., 2018). We assessed the efficiency of HIV-1 reverse 
transcription in HEK293T cells where levels of each eEF1A paralog were modulated. In repeated 
experiments we observed a statistically significant effect on late, but not on early, DNA synthesis 
when the endogenous A1 was downregulated by over 80%; which agreed with our previous report 
(Warren et al., 2012). Overexpression of exogenous A1, but not A2 restored HIV-1 late DNA 
synthesis. In all experiments, we noted a slight negative effect of A2 overexpression on late DNA 
levels in HEK293T cells with control siRNA, which was not observed when A1 was overexpressed 
or in A2 overexpression in siRNAA1 cells. We speculate that a competition between exogenous A2 
and endogenous A1 may account for this small effect. The results revealed that HEK293T cells 
predominantly express A1 protein, but also express A2 at very low levels as determined by A2 
mRNA analysis. The level of A1 mRNA, not A2 mRNA, correlated with the HIV-1 reverse 
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transcription efficiency in HEK293T cells and SKMCs, providing strong support to the finding that 
A1, not A2, is important for HIV-1 reverse transcription.   
The A1 and A2 paralogs share a canonical activity in protein synthesis (Kahns et al., 1998), 
but they are expressed in distinctly different tissues. Analysis shows that A2 is expressed 
predominantly in terminally differentiated muscle and neurons while A1 is ubiquitously expressed in 
nearly all other tissues. The different non-canonical functions of A1 and A2 may explain the why the 
expression of genes encoding two eEF1A paralogs with such a high amino acid identity and 
similarity are differentially regulated in different tissues (Soares and Abbott, 2013). For example, A1 
has reported pro-apoptotic activity while A2 has anti-apoptotic effects on cells (Hotokezaka et al., 
2002). Further emerging evidence that the two eEF1A paralogs have key structural variations, 
mainly in surface clusters where differences in post-translational modifications (including 
acetylation, phosphorylation, S-nitrosylation and ubiquitination) and hydrophobic properties, may 
underlie their ability to undertake their non-canonical cellular activities (Soares and Abbott, 2013; 
Soares et al., 2009; Timchenko et al., 2013). For example, a recent paper reported that A1, but not 
A2, can bind with Ca
2+
 calmodulin and that this interaction affects their differences in actin binding 
properties (Novosylna et al., 2017). Also, evidence that inappropriate expression of A2 in cells which 
normally only express A1 plays a role in tumorigenesis suggests that the two eEF1A paralogs 
participate in fundamentally different interactions in the cellular proteome and therefore take on 
unique functional and expression profiles (Abbas et al., 2012; Abbas et al., 2015). These differences 
in regulation of cellular functions may also impact on HIV-1 reverse transcription efficiency. For 
example, actin is involved in uncoating and reverse transcription (Bukrinskaya et al., 1998), and 
differential regulation of actin by A1 or A2 may indirectly affect reverse transcription, as we recently 
reported with RSV replication (Snape et al., 2018). 
In conclusion, the A1 paralog binds HIV-1 RT with more stability than the A2 paralog, and 
only the A1 paralog correlated with reverse transcription efficiency. Therefore, the A1 paralog, but 
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not the A2 paralog, is important for HIV-1 infection. HIV-1 replicates in various human cells, 
including CD4
+
 T cells and macrophages, and the CD4 cell surface receptor is a main factor 
determining cellular cytotropism. However, CD4 negative and A1 paralog dominant epithelial cells 
of the liver, kidney, and in mammary epithelial cells of HIV-1 infected women are reported to 
support HIV-1 replication (Kandathil et al., 2016). Alternatively there are controversial reports of 
HIV-1 infection of neurons and, to our knowledge, no reports of HIV-1 in muscle cells, which both 
only express A2 (Balinang et al., 2017; Canto-Nogues et al., 2005). The expression profiles of A1 
and A2 paralogs of eEF1A may have broad implications in understanding replication of HIV-1 and 
other viruses, and cytotropism of these viruses. 
 
 
4. Materials and methods 
4.1. Cells and virus culture. HEK293T cells were grown in Dulbecco's modified Eagle's medium 
supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 I.U./ml)-streptomycin (50 
µg/ml). The human skeletal muscle cells were bought from Lonza Walkersville (USA) and cultured 
in the growth medium as per manufacturer instructions. Differentiation of myotubes was achieved by 
replacing growth medium with DMEM-F12 (Lonza, USA) supplemented with 2% horse serum 
(Sigma, USA). All cell lines were incubated at 37°C in 5% CO2. The stock of VSV-G pseudotyped 
HIV-1NL4-3 or HIV-1pNL4-3.Luc.R-E were generated by co-transfection of a proviral DNA plasmid and 
VSV-G plasmid into HEK293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) 
according to the manufacturer's recommendations. Cell culture supernatants were collected at 48 h 
post-transfection and centrifuged (200 × g, 10 min), and the supernatant was filtered (0.45 μm) and 
stored in 1 ml aliquots at −80°C.  
4.2. Co-immunoprecipitation (Co-IP) . Co-IP was performed as elsewhere described (Warren et 
al., 2012). Briefly, HEK293T cells were co-transfected with plasmids to express HIV RT-V5 and 
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over-express eEF1A1-flag or eEF1A2-flag. The cells were lysed at 24 h post-transfection in S100 
buffer (10 mM Tris, pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 1× complete protease inhibitor cocktail 
[Roche], and 0.5 mM β-mercaptoethanol) using a Dounce homogenizer. The lysate was cleared by 
centrifugation in a microfuge (4°C, 20,000 x g, 10 min). The supernatant was incubated with anti-
flag rabbit antibody coupled Dynabeads Protein G (Invitrogen, USA) for 2 h at 4°C. The 
immunoprecipitate was washed three times with S100 buffer plus 0.3% of Triton-x100 followed by 
western blot analysis using anti-V5 mouse antibody.  
4.3. Purification of eEF1A1 and eEF1A2 from mouse tissue. A1 and A2 were purified from adult 
mouse liver and skeletal muscle respectively using two consecutive ion-exchange column-
chromatography steps according to a published method (Yaremchuk et al., 2012). The approval to 
obtain mouse tissue used in the experiment was provided by QIMR Berghofer Medical Research 
Institute Animal Ethics Committee. Briefly, 10 g of mouse liver or skeletal muscle was homogenized 
in 20 ml buffer A (30 mM potassium phosphate pH 7.5, 1 mM MgCl2, 15% glycerol, 6 mM β-
mercaptoethanol supplemented with 1 mM PMSF) using a tissue grinder. After 40 min of 
centrifugation at 12,000  g, the supernatant was filtered through four layers of sterile gauze to 
remove fat. The clear supernatant was loaded onto a DEAE-cellulose column (GE Healthcare) 
previously equilibrated with buffer A. Unbound proteins were collected and loaded directly onto an 
SP-Sepharose column (GE Healthcare) equilibrated with buffer A. The column was extensively 
washed with buffer A containing 100 mM KCl until the OD at 280 nm reached the baseline. eEF1A1 
and eEF1A2 were eluted from the column with 5 column volume of 200 mM KCl in buffer A and 
dialyzed against storage buffer (25 mM potassium phosphate pH 7.5, 1 mM MgCl2, 25% glycerol, 2 
mM DTT). The presence and purity of eEF1A1 and eEF1A2 were examined by SDS–PAGE 




4.4. BLI assay. The purified recombinant 6His-tagged HIV-1 RT p51/ p66 (gift from Stuart 
LeGrice, Duane Grandgenett) were biotinylated using EZ-Link Sulfo-NHS-Biotin following the 
manufacturer’s instructions (Pierce Biotechnology, IL, USA) and immobilized onto OctetRed system 
streptavidin-coated biosensors (Pall ForteBio, CA, USA). A standard kinetic buffer (1 mM 
phosphate, 15 mM NaCl, 0.002% Tween-20 and 0.1 mg/ml gelatine) was used in all experiments 
unless noted. The association (ka) of the two proteins was measured by incubating ligand biosensors 
(biotinylated protein) into kinetic buffer containing protein (analyte) with 1000 rpm shaking in the 
OctetRed system. Concentrations of analyte ranging from 90 nM to 10 nM were assayed. The 
dissociation (kd) was determined by moving the ligand biosensor from kinetic buffer containing 
analyte to the standard kinetic buffer.  
4.5. Plasmids. For expression of HIV-1 RT p51 in cells, the coding DNA sequences were amplified 
from pHGPsyn construct (Wagner et al., 2000), which contains a codon optimized Gag-Pol 
sequence, and was inserted into pDONR vector using Gateway system (Invitrogen, USA) by a BP 
recombination reaction. The inserts were then transferred into destination mammalian expression 
vectors that contain V5 tags by LR recombination reactions. The same strategy was used to construct 
A1 and A2 expressing plasmid and the proteins were fused with a FLAG tag. The cDNA templates 
were obtained from PlasmID Repository (Harvard).  
A1 cDNA sequence was modified to be resistant to siRNA SASI_Hs02_00331772 by mutation of 
the original A1 cDNA. The modified eEF1A1 (Res-A1) and A2 DNA fragments were excised with 
NheI and EcoRI and inserted into a pSicoR-EF1a vector (Addgene, Cambridge, MA) at these 
restriction enzyme sites (Jin et al., 2016) to give the pSicoR-Res-A1 and pSicoR-A2 vectors. 
4.6. siRNA treatment. siRNA (Sigma-Aldrich) targeting A1 (siRNA ID: SASI_Hs02_00331772) 
and control siRNA (SIC001) were applied to HEK293T cells by large-scale reverse transfection 
using Lipofectamine RNAiMAX according to the manufacturer’s instructions (Invitrogen). 
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4.7. VLP production and transduction. VLPs that convey Re-A1 or A2 were produced by co-
transfecting 3 µg of pSicoR-Res-A1 or pSicoR-A2 with 10 µg of plasmid pCMVΔR8.91 and 3 µg of 
pCMV-VSV-G into HEK293T cells with X-tremeGENE HP DNA transfection reagent (Roche 
Diagnostics GmbH, Mannheim, Germany) in accordance with the manufacturer’s protocol. The cell 
medium was replaced at 24 h post-transfection. VLPs were harvested by filtration with a sterile 0.2-
µm syringe filter (Sartorius Stedim Biotech GmbH, Göttingen, Germany) at 48 h post transfection. 
The concentration of VLPs was quantified with a RETROtek HIV-1 CAp24 antigen ELISA 
(Zeptometrix, USA). For transduction, Res-A1 or A2 VLPs were incubated with HEK293T cells in 
the presence of 8 µg/ml of hexadimethrine bromide (Sigma-Aldrich) and the positive cells were 
sorted with a MoFlo High Speed Cell Sorter (Beckman Coulter, Pasadena, CA) at 3 day post-
transduction. 
4.8. Virus infection, DNA extraction and analysis of reverse transcription DNA synthesis. 
HIV-1NL4.3 virus stock was treated with DNase I at 37 °C for 30 min to remove any DNA 
contamination prior to adding to cells. HEK293T cells were incubated with HIV-1NL4.3 VSV-G 
pseudotyped virus in presence of 8 µg/ml polybrene at 4°C for 2 h and then 37 °C for 4 h. For 
SKMCs infection, HIV-1pNL4-3.Luc.R-E VSV G pseudotyped virus was used and the infection was 
performed with centrifugation at 1,200  g, 16 °C for 2 h and then 37 °C for 4 h. The cells were then 
washed three times with 0.1 mM EDTA PBS, and lysed using Glo Lysis Buffer (Promega). The 
lysate was centrifuged (20,000  g, 10 min) and the supernatant was extracted once with an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) and once with chloroform. The extracts 
were ethanol precipitated, washed with 70% (vol/vol) ethanol, and resuspended in 0.1 mM EDTA. 
The early and late HIV-1 reverse transcription products were analyzed by quantitative PCR using 
specific primers as elsewhere described (Warrilow et al., 2008) . 
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4.9. RNA extraction and A1, A2 paralog specific RT-qPCR. RNA extraction was performed using 
TRIzol reagent (Invitrogen, USA) following the manufacturer’s instructions. Reverse transcription 
was carried out using random primers and superscript III reverse transcriptase (Invitrogen, USA). A1 
and A2 paralog specific detection is achieved by using specific primers in qPCR. The primer 
sequences for A1 paralog are GACCAGCAAGTACTATG (forward) and 
CCAAGCTTCAAATTCACCA (reverse). The sequences of primers for A2 paralog are 
GACCACCAAGTACTACA (forward) and ATGCCCGCCTCGAACTCG. The cellular gene 
GAPDH was used as internal controls. 
4.10. Statistical analysis. Statistical analyses were performed using a student’s unpaired T-test with 
Welch’s correction for least three independent experiments or measurements. Statistical significance 
was set at p < 0.05. The correlation analysis was performed using Graphpad software. The 
correlation coefficient, r
2
 =1 indicating a perfect correlation and r
2
 =0 means the two variables do not 
correlate at all. 
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Figure legends 
Fig 1. The A1 paralog of eEF1A binds RT stronger than the A2 paralog by co-IP in HEK293T 
cells. (A-C) The pDEST-HIV-RTp51-v5 expression plasmids were transfected alone or co-
transfected with pDEST-A1-FLAG or pDEST-A2-FLAG into HEK293T cells. A cell lysate was 
made 24 h post-transfection and analyzed by western blot. RT-v5, or A1-FLAG and A2-FLAG were 
detected by western blot using anti-V5 or anti-FLAG antibodies, respectively. An anti-β-tubulin 
antibody was used to detect β-tubulin. Co-IP assays were performed using anti-FLAG antibody 
labeled beads. The beads were washed in buffer and the level of RT (D) or A1-FLAG and A2-FLAG 
(E) in IP product was detected by western blot using anti-V5 or anti-FLAG antibodies as shown. The 
experiment was performed three times with similar results. A representative experiment is shown. 
The relative RT signal was quantified using ImageJ software and normalized to the FLAG (A1 and 
A2) signal, and presented as mean of three separate western blot results (F).  
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Fig 2. The interaction of RT with purified A1 and A2 show distinct binding kinetics. (A) The 
purified A1 from mouse liver and A2 from mouse muscle were analyzed by SDS-PAGE and 
visualized with Coomassie brilliant blue stain. (B) 100 and 400 ng of A1 and A2 proteins were 
examined by western blot using anti-eEF1A2 and anti-eEF1A antibodies. (C) The total RNA was 
extracted from mouse liver and skeletal muscle tissue followed by RT using random primer and 
qPCR using A1 and A2 specific primers. The level of RNA in each tissue is presented as the mean 
value of repeated PCR reactions. (D) Distinct binding kinetics observed for A1 and A2 interaction 
with HIV-1 RT in biolayer interferometry assays. Biotinylated HIV RT was immobilized on 
streptavidin biosensors and incubated with 90, 30 and 10 nM of purified A1 or A2 protein analytes 
and real-time binding was measured using the Octet RED system (Li et al., 2015b). 
Fig 3. Exogenously expressed ResA1, but not A2, restores reverse transcription efficiency in A1 
down-regulated cells. (A) The lentiviral vector pScioR-EF1α was used to deliver mCh-T2A-ResA1 
or mCh-T2A-A2 to HEK 293T cells by transduction. Res-A1 has the same amino acid sequence as 
endogenous A1 but is resistant to siRNAA1. The T2A ribosomal skipping sequence permits 
independent translation of mCh-T2A and Res-A1 or A2. Due to T2A skipping, exogenous ResA1 
and A2 proteins have an additional proline residue on the N-terminus. The mCh-T2A positive cells 
were purified by FACS. (B) Parental HEK 293T cells (cells only sample) or HEK 293T cells over 
expressing exogenous ResA1 or A2 were treated with siRNAA1 that targets endogenous A1 mRNA, 
or a siRNAC as a control as indicated. At 48 h post-treatment, a cell lysate was made and the level of 
eEF1A in the samples was detected by western blot using an anti-eEF1A polyclonal antibody. This 
includes endogenous A1 and exogenously expressed ResA1 or A2 (upper panel). A western blot of 
the same lysate for β-tubulin is shown (lower panel). The signal was quantified using ImageJ and 
normalised to the signal of the control siRNA sample. (C and D) The cells were infected with HIV-
1pNL4-3.Luc.R-E pseudotyped with VSV-G by incubation with the cells for 2 h at 4 °C to allow virus 
attachment, and then at 37 °C for 4 h to initiate virus entry and reverse transcription. Cell lysates 
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were made from the infected cells and the levels of HIV-1 early and late reverse transcribed DNA in 
each sample were measured by qPCR as previous described (Warren et al., 2012). (E) The reverse 
transcription efficiency was calculated as the ratio of late DNA to early DNA as a percentage. The 
mean of at least three experiments and the standard deviations are shown. P values of comparisons 
that had statistically significant differences are shown. 
Fig 4. HIV-1 reverse transcription efficiency correlated with the level of eEF1A1, not eEF1A2 
in HEK293T cells. A1, A2 and GAPDH mRNA copied were measured by RT-qPCR from RNA 
extracted from cells. The HIV-1 reverse transcription early and late DNA products were measured by 
qPCR from cell lysates prepared at 4 h post-infection with HIV. The A1 or A2 mRNA copy number 
were normalized to GAPDH mRNA. RT efficiency was calculated by copy number of late 
DNA/copy number of early DNA. The data is presented as mean ± SD from three independent 
experiments. Correlation analysis was performed between the relative levels of A1 (A) or A2 (B) 
with the RT efficiencies. The value of r
2
 approaching 1 indicates high correlation, while approaching 
0 indicates low correlation. 
Fig 5. Overexpression of Res-A1 increases HIV-1 reverse transcription efficiency in SKMCs. 
Untreated SKMCs, SKMCs expressing Res-A1 (SKMCs-Res-A1), A2 (SKMCs-A2) or mCh-T2A 
(SKMCs-mCh) were infected with HIV-1pNL4-3.Luc.R-E pseudotyped with VSV-G at 1,200  g at 16°C 
for 2 h, and then incubated at 37°C for 4 h or 24 h. The 4 h sample cell lysates were prepared for (A) 
early and (B) late HIV-1 DNA detection by qPCR, and (C) is the ratio of late/early DNA. (D) 
SKMCs expressing mCh, Res-A1 or A2 were infected with HIV-1pNL4-3.Luc.R-E pseudotyped with 
VSV-G for 48 h and luciferase in cell lysates were measured using firefly luciferase. The mean of at 
least three experiments and the standard deviations are shown. P values for observations that had 
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